Real-world treatment patterns and total cost of care in Medicare patients with metastatic pancreatic ductal adenocarcinoma who received first-line FOLFIRINOX

被引：0
|
作者：
Hirsch, Jared
Cockrum, Paul
Tomicki, Samantha
Dieguez, Gabriela
Bhatt, Prachi
Kim, George P.
机构：
[1] Milliman Inc, New York, NY USA
[2] Ipsen Biopharmaceut Inc, Crowley, TX USA
[3] George Washington Univ, Washington, DC USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16283
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Cost-effectiveness of FOLFIRINOX for first-line treatment of metastatic pancreatic cancer.
    Attard, Cheryl L.
    Brown, Stephen
    Alloul, Karine
    Moore, Malcolm J.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
  • [22] Real-world study of treatment patterns and outcomes among patients with metastatic pancreatic ductal adenocarcinoma (PDAC) in Europe.
    Taieb, Julien
    Hammel, Pascal
    Reni, Michele
    Palmer, Daniel H.
    Bridgewater, John A.
    Cubillo, Antonio
    Prager, Gerald W.
    Vermeire, Alice
    D'Esquermes, Nathalie
    Biville-Hedouin, Fabienne
    Teng Zhaoyang
    Seufferlein, Thomas
    Macarulla, Teresa
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [23] Assessing real-world survival outcomes of patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with first-line FOLFIRINOX compared to patients from a phase 1/2 trial treated with NALIRIFOX.
    Zhu, Xuelian
    Cockrum, Paul
    Shah, Bonny
    Parzynski, Craig
    Garawin, Tamer
    Maxwell, Fiona
    Surinach, Andy
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [24] Real-world patterns of pain medication use among patients with metastatic pancreatic ductal adenocarcinoma (mPDAC)
    Laursen, Ashley Ann
    Surinach, Andy
    Wang, Shu
    Cockrum, Paul
    George, Ben
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (28)
  • [25] First-line gemcitabine plus nab-paclitaxel versus FOLFIRINOX for metastatic pancreatic cancer in a real-world population
    Hatashima, Alycia
    Arango, Matthew J.
    Reardon, Joshua
    Freeman, Tracelyn
    Williams, Terence
    McLaughlin, Eric M.
    Abushahin, Laith
    FUTURE ONCOLOGY, 2022, 18 (20) : 2521 - 2532
  • [26] Comparison of treatment patterns, resource utilization, and cost of care in patients with metastatic pancreatic cancer treated with first-line nab-paclitaxel plus gemcitabine or FOLFIRINOX
    Kim, George P.
    Parisi, Monika F.
    Patel, Manish B.
    Pelletier, Corey L.
    Belk, Kathy W.
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2017, 10 (05) : 559 - 565
  • [27] Comparison of FOLFIRINOX vs Gemcitabine Plus Nab-Paclitaxel as First-Line Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma
    Klein-Brill, Avital
    Amar-Farkash, Shlomit
    Lawrence, Gabriella
    Collisson, Eric A.
    Aran, Dvir
    JAMA NETWORK OPEN, 2022, 5 (06) : E2216199
  • [28] First-line systemic real-world treatment of patients with advanced/metastatic NSCLC in the UK
    Wang, M.
    Dhokia, P.
    Menon, S.
    Martindale, B.
    ANNALS OF ONCOLOGY, 2018, 29 : 22 - 22
  • [29] INCIDENCE OF NEUTROPENIA IN PATIENTS RECEIVING EITHER NABPACLITAXEL PLUS GEMCITABINE OR FOLFIRINOX AS FIRST-LINE TREATMENT FOR METASTATIC PANCREATIC ADENOCARCINOMA
    Parisi, M.
    Patel, M.
    Belk, K.
    Craver, C. W.
    VALUE IN HEALTH, 2016, 19 (03) : A141 - A141
  • [30] Real-World Assessment of Health Care Costs for Patients with Metastatic Pancreatic Cancer Following Initiation First-Line Chemotherapy
    Bullock, Andrea
    Rowan, Christopher G.
    Oestreicher, Nina
    Yeganegi, Homa
    Chiorean, E. Gabriela
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2020, 26 (07): : 872 - 878
12345